Date Modified: May 29, Clinical Quality Measures for PQRS
|
|
- Bonnie Hamilton
- 5 years ago
- Views:
Transcription
1 Date Modified: May 29, 2014 Clinical Quality s for PQRS
2 # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3 Efficiency and Cost Reduction QCDR-4 QCDR-5 QCDR-6 Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Unplanned Hospital Admission within 30 Days of TRUS Biopsy: Percentage of biopsies where patients aged 30 years and had an unplanned hospital admission within 30 days of biopsy Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a CT scan performed at any time since diagnosis of Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist) Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pt category, the pn category, the Gleason score and a statement about margin status Prostate Cancer: Proportion of patients with low-risk receiving active surveillance Prostate Cancer: Percentage of cases with a length of stay > 2 days Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy: Percentage of patients aged 30 years and who had an unplanned hospital readmission within 30 days of principal procedure # of prostate biopsies for patients aged 30 or # of prostate biopsies for patients aged 30 or PQRS See cancer patients 30 years or receiving brachytherapy, EBRT, RP, or cryotherapy PQRS See PQRS See PQRS See cancer patients 30 or # of patients aged 30 or who underwent a radical prostatectomy as treatment for # of radical prostatectomies for patients aged 30 or # of biopsies where a compliant antibiotic regimen was given # of biopsies where a hospital admission resulted within 30 days of the procedure PQRS See # of low risk prostate cancer patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of prostate cancer PQRS See PQRS See PQRS See cancer patients on active surveillance # of patients with a length of stay > 2 days after radical prostatectomy # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure Non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment Biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment age; patients receiving an alternate form of treatment from those specified; patients that have had prior treatment age; patients that have had prior treatment age; patients that have had prior treatment Prostatectomies performed in patients < 30 years of age; patients that have had prior treatment Evidence-based care Metric of safety of medical care PQRS See Metric of appropriate resource utilization PQRS See PQRS See PQRS See Metric of patientcentered decision making Metric of appropriate resource utilization Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 2
3 Non-PQRS #1 ( QCDR-1): Prostate Biopsy Antibiotic Compliance Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Patient safety # of biopsies where a compliant antibiotic regimen was given # of prostate biopsies for patients aged 30 or Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for Evidence-based care Non-PQRS # 2 ( QCDR-2): Unplanned Hospital Admissions within 30 days of TRUS Biopsy Percentage of biopsies where patients aged 30 years and had an unplanned hospital admission within 30 days of biopsy clinical care # of biopsies where a hospital admission resulted within 30 days of the procedure # of prostate biopsies for patients aged 30 or Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 3
4 Non-PQRS # 3 ( QCDR-3): Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients Percentage of patients, regardless of age, with a diagnosis of at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of Efficiency and cost reduction # of low risk patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of # of low-risk patients 30 years or receiving brachytherapy, EBRT, RP, or cryotherapy Excludes patients < 30 years of age; patients receiving an alternate form of treatment from those specified; patients that have had prior treatment Metric of appropriate resource utilization Non-PQRS # 4 ( QCDR-4): Prostate Cancer: Proportion of Patients with Low-Risk Prostate Cancer Receiving Active Surveillance Proportion of patients with low-risk receiving active surveillance clinical care # of low-risk patients on active surveillance # of prostate biopsies for patients aged 30 or Excludes patients < 30 years of age; patients that have had prior treatment Metric of patient-centered decision making Michigan Urological Surgery Improvement Collaborative () QCDR Page 4
5 Non-PQRS # 5 ( QCDR-5): Prostate Cancer: Percentage of Prostate Cancer Cases with a Length of Stay > 2 Days Percentage of radical prostatectomy cases with a length of stay > 2 days clinical care # of patients with a length of stay > 2 days after radical prostatectomy # of patients aged 30 or who underwent a radical prostatectomy as treatment Excludes patients < 30 years of age; patients that have had prior treatment Metric of appropriate resource utilization Non-PQRS # 6 ( QCDR-6): Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy Percentage of patients aged 30 years and who had an unplanned hospital readmission within 30 days of principal procedure clinical care # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure # of radical prostatectomies for patients aged 30 or Excludes prostatectomies performed in patients < 30 years of age; patients that have had prior treatment Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 5
Date Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationNon-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys
Non-QPP Measures # Measure Title Definition Type Domain 1 Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Percentage of patients (boys) =< 18 years of age newly diagnosed with undescended
More informationcreatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed
Non-QPP Measures # Measure Title Definition Type Domain 1 Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Percentage of patients (boys) =< 18 years of age newly diagnosed with undescended
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationNon-QPP Measures 3 AQUA12. 6 AQUA15 Stones: Urinalysis documented 30 days before
Non-QPP Measures 1 Measure ID Measure Title Definition Type Domain AQUA3 (inverse) Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Percentage of patients (boys) =< 18 years of age
More informationPercentage of patients who underwent endoscopic procedures following SWL
Non-QPP Measures Measure ID Measure Title Definition Type Domain 1 AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis Percentage of patients with NEW diagnosis of clinically significant
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More information2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures
2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general
More informationNATIONAL QUALITY FORUM
Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy
More informationIdentifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist
Identifying Initial Populations and Sampling for OCM and EBRT Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist January 22, 2015 Learning Objectives Help participants to understand
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationOne Stop Prostate Biopsy Protocol Author Consultation Date Approved
One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationMeasure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationQuality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationThe European Board of Urology
Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationAQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)
AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis with NEW diagnosis of clinically significant BPH who had IPSS (international prostate symptoms score) or AUASS (American urological
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationMichigan Urological Surgery Improvement Collaborative
Michigan Urological Surgery Improvement Collaborative Making Michigan #1 in Prostate Cancer Care Jim Montie, MD Susan Linsell, MHSA February 10, 2015 Vital statistics MUSIC Participants: 42 practices 235
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationTroubleshooting Audio
Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines
More informationPhysician Self-Referral: Recent Research from the Government Accountability Office (GAO)
Physician Self-Referral: Recent Research from the Government Accountability Office (GAO) James C. Cosgrove, Ph.D. National Health Policy Forum July 18, 2014 Self-Referral: Background Physician self-referral
More informationClinical Quality Measures for PQRS. Last Updated: June 4, 2014
Clinical Quality Measures for PQRS Last Updated: June 4, 2014 The Michigan Bariatric Surgery Collaborative (MBSC) Quality Clinical Data Registry will submit the following measures outlined below on behalf
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationCommissioning Urology Services in New NHS
Commissioning Urology Services in New NHS Oct 2013 Commissioning Urology Services NHS England s Role Role of the new Clinical Reference Groups Current Issues / Work Programme for Urology Clinical Reference
More informationIQSS 2019 QCDR and MIPS Measure Specifications
IQSS1 Hypogonadism: Serum T, CBC, PSA, IPSS within 6 months of Rx Percentage of patients with a Effective Clinical Patients with documented new diagnosis of hypogonadism receiving androgen replacement
More informationHow do I control (monitor) patients receiving TRT after prostate cancer treatment
How do I control (monitor) patients receiving TRT after prostate cancer treatment Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationPossible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436
2015 Individual PQRS s Eligible OMS #22: Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non- Cardiac Procedures) Percentage of noncardiac surgical patients aged 18 years and older undergoing
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationTable 1 Standards and items to set up a PCU: general requirements and critical mass
Table 1 Standards and items to set up a PCU: general requirements and critical mass General requirements and European Prostate Cancer Units are structures managing sufficient volumes of patients with on-site
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More information2014 Oncology Measures Group Overview
2014 Oncology Measures Group Overview The Oncology Measures Group is a reporting option that significantly reduces the burden of participation in the Physician Quality Reporting System (PQRS). Source:
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationCauses of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer
Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationTechnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546
Padeliporfin for untreated localised prostate cancer Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationTHE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES
THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES OVERVIEW Diagnosis Laboratory Tests PSA Free and Total PSA PCA-3 4K Score The
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationMeasure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management
Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (625) Measure Code: PRS Rule : Applicable Provider Specialty: General Criteria Summary Steward: Active Health Management Lab Data: Y Percentage
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationPPS Exempt Cancer Hospital Quality Reporting (PCHQR) Program Relationship Matrix of Program Measures by Years and Quarters
PPS Exempt Cancer Quality (PCHQR) Relationship Matrix of Measures by and This reference document for PCHQR participants provides the following: Specific measures with their National Quality Forum (NQF)
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationTo treat or not to treat: When to treat! A case presentation
To treat or not to treat: When to treat! A case presentation Filip Ameye, MD,Phd Universitary Hospitals Leuven, Belgium Departement of Urology Prostate Center A case presentation Pt. 76 y. Mild LUTS (07/1999)
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationMeaningful Use Clinical Quality Measures for Eligible Professionals
Meaningful Use Clinical Quality Measures for Eligible Professionals Measure Type NQF ID CMS ID Description Title: Adult Weight Screening and Follow-Up 1 NQF 0421 PQRI 128 calculated BMI in the past six
More informationPRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES
PRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES Day 3 Authors: Tade, Funmilayo; Akin-Akintayo Oladunni; Schuster, David M. Lab Training Module 1: Introduction to the basics of
More informationR-SCAN: Engaging Clinicians in Value-based Care
R-SCAN: Engaging Clinicians in Value-based Care Nancy Fredericks, MBA R-SCAN Director rscan.org What is R-SCAN? A collaborative between referring clinicians and radiologists to improve patient care R-SCAN
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationBLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER
BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationPPS Exempt Cancer Hospital Quality Reporting (PCHQR) Program Relationship Matrix of Program Measures by Years and Quarters
PPS Exempt Cancer Quality (PCHQR) Relationship Matrix of Measures by and This reference document for PCHQR participants provides the following: Specific measures with their National Quality Forum (NQF)
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationNQF Measure Number & PQRI Implementation Number
Title NQF Steward s Adult Weight Screening and Follow-Up Hypertension: Blood Pressure ment Preventive Care and Screening Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention with a calculated
More informationTroubleshooting Audio
Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines
More information2017 Merit-based Incentive Payment System. Avoiding the Penalty
2017 Merit-based Incentive Payment System Avoiding the Penalty 1 What is the Quality Reporting Program? Quality Payment Program (also known as MACRA) Advanced Alternative Payment Models (APMs) Merit-based
More informationCancer Center Dashboard
Cancer Center Dashboard Measure Definition Benchmark Endorsed By Screening Breast Cancer Screening Percentage of eligible women 40-69 who received a mammogram within the past 24 months NCQA reported average:
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More information[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK
06 March, 2018 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK Document Filetype: PDF 506.4 KB 0 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK See information on benefits and safety. We
More information2014 AUA Annual Census
2014 AUA Annual Census PUBLIC USE MICRO DATASET Data Elements Variable Name Type Variable Description Length Position ID Number Encrypted identification Number 8 1 G3_2 Number Year of graduation: MD (Doctor
More informationClinical Quality Measures for Submission by Medicare or Medicaid EP/s for the 2011 and 2012 Payment Year
1 NQF 0059 1 NQF 0064 2 NQF 0061 3 Title: Diabetes: Hemoglobin A1c Poor Control Description: Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c > 9.0%. Title:
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationGuideline Prostate cancer: diagnosis and management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Prostate cancer: diagnosis and management (update) Draft for consultation, December 0 This guideline covers diagnosing and managing prostate
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More information